Every 8-K that Helix Acquisition Corp. II (HLXB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HLXB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLXB filings page.
BridgeBio Oncology Therapeutics, Inc. completed its business combination on August 11, 2025, when Helix Acquisition Corp. II domesticated to Delaware, merged with TheRas, Inc. (d/b/a BBOT) and changed its name to BridgeBio Oncology Therapeutics, Inc. At closing PubCo listed on Nasdaq under the symbol BBOT. PubCo received gross proceeds of approximately $381.8 million before transaction expenses, including $120.9 million from Helix's trust account and $260.9 million from a concurrent PIPE of 24,343,711 shares at $10.7173 per share. Helix Class A shareholders redeemed 7,119,750 shares for an aggregate of approximately $76.3 million.
Pro forma shares outstanding include 79,196,710 PubCo Common Stock. Approximately 61.1 million shares (about 77.2%) are subject to registration rights. The registry of new governance and compensation arrangements includes appointments of Eli Wallace as CEO, Uneek Mehra as CFO, Pedro Beltran as CSO and Yong Ben as Chief Medical and Development Officer, executive base salaries (e.g., Wallace $550,800) and approved equity plans (2025 Plan initial reserve 5,373,641 shares; ESPP initial reserve 895,607 shares). The company dismissed WithumSmith+Brown and engaged Deloitte; Withum's report included an explanatory going concern paragraph for Helix as of December 31, 2024.
Helix Acquisition Corp. II (Nasdaq: HLXB) has reached a key milestone in its proposed merger with TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics, “BBOT”). The company disclosed in an 8-K filing dated 11 July 2025 that the U.S. Securities and Exchange Commission declared the joint Registration Statement on Form S-4 effective on 10 July 2025. The effective S-4 contains the combined proxy statement/prospectus that will be mailed to Helix shareholders of record as of 30 June 2025 for a vote on the business combination.
Under the Business Combination Agreement (signed 28 Feb 2025 and amended 17 Jun 2025), Helix will merge with BBOT through a wholly owned subsidiary, after which the resulting public entity will be renamed BridgeBio Oncology Therapeutics (“PubCo”). The filing notes that completion of the transaction remains subject to customary conditions, including shareholder approval and possible regulatory clearances. Exhibit 99.1 (press release) was furnished—not filed—under Item 7.01.
The filing reiterates extensive forward-looking statement and risk disclosures typical of SPAC transactions, highlighting uncertainties such as shareholder redemptions, regulatory review, clinical-development outcomes for BBOT’s candidates (ONKORAS-101, BREAKER-101, BBO-11818, BBO-8520, BBO-10203) and general market conditions.
- Next step: distribution of the definitive proxy statement/prospectus to shareholders and scheduling of the shareholder meeting.
- Ticker and listing: Helix’s Class A ordinary shares continue to trade on Nasdaq under “HLXB” until closing.